Abgenix, Inc. (ABGX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Abgenix, Inc. (ABGX)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (61)	11/30/2001 7:24:28 AM
From: Icebrg	Read Replies (2) of 590

Following Abgenix's recent conference call Adams Harkness & Hill in a research note provided the following summary regarding the company's clinical development status. - ABX-IL8: The Company plans to complete enrollment in a Phase IIb study in patients with moderate-to-severe psoriasis this year, with results expected to follow in Q2 of 2002. If the data are positive, a bridging study with an intramuscular and/or subcutaneous formulation would begin in H2 of 2002, followed by Phase III trials with the new formulation in H1 of 2003. In addition, a Phase IIa proof-of-concept trial with ABX-IL8 in rheumatoid arthritis is fully enrolled. Data are expected in Q1 of 2002 (likely January). Finally, enrollment in a Phase IIa study in patients with COPD is expected to be complete by Q3 of 2002, with data to follow in Q1 of 2003. - ABX-EGF: Phase II trials with ABX-EGF continue in kidney cancer and NSCLC. A third Phase II trial will be initiated with collaborator Immunex by the end of this year (likely in colorectal or pancreatic cancer). Two additional Phase II studies are expected to begin in 2002 for other EGF-expressing cancers. Results from the Phase II trial in kidney cancer are expected by the middle of 2002. - ABX-CBL: Enrollment in the Phase II/III graft-versus-host disease trial is expected to be complete by the end of 2002, with data available in Q1 of 2003. - An IND for the fourth Abgenix product is to be filed by the end of this year. - The Company expects to have 11 product candidates by the end of 2002, seven of which will be in Phase II or Phase III trials, and 18 product candidates by the end of 2003, 11 of which will be in Phase II or Phase III trials. The staggering number of product candidates in the clinic towards the end of 2002 includes products being developed by Abgenix's licencees. Still, it is not a bad figure. Ice

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next